2014
20
14
ACTIVITY REPORT
EDITORIAL
In line with the sharp increase of its partnering R&D revenues since its accreditation as a Carnot institute, CALYM has benefited from a new year of growth in 2014, reaching a new record of income from its R&D collaborations with the industry. This is the result of the enthusiastic work performed by the 13 different entities members of our consortium, whose research and innovation capacity is unparalled in the
Pascal DESCHASEAUX General Manager
lymphoma field, and by an operational team progressive strengthening. Such activity was characterized again by a strong presence of big pharma partners and our institute will have to transform the opportunities for partnerships with biotech/ diagnostic companies currently discussed, as they represent the more labile SME segment in the lifescience sector. For this, CALYM relies, on top of its own communication, on the international business development means of the GLOBAL CARE consortium. Based upon the above, 2015 should be again a positive year for our young institute in terms of development, with the contribution of the numerous internal R&D programs we have funded, as well as that of the progressive exploitation of the CeVi cell collection, a platform that is generating its first partnerships with the industry. Moreover, we are proud that our institute obtained in 2014 the ISO 9001 : 2008 certification for ACTIVITY REPORT 2014
the management and follow-up of partnering research: it validates the quality assurance strategy we are developing towards the industry. Last but not least, CALYM has been strongly contributive to the activities of the Carnot Institutes Association and has benefited from them, particularly the opportunity to learn from good practices of the other Carnot institutes. We are convinced that 2015 will be a new positive year for the construction of a leading institute for research and innovation in our field.
2
TABLE OF CONTENTS
HIGHLIGHTS OF 2014
4
BTAINING THE ISO 9001:2008 CERTIFICATION O FOR THE MANAGEMENT AND MONITORING OF PARTNERING RESEARCH ACTIVITIES
4
CALYM SCIENTIFIC AND PARTNERING DAY
4
RESPONSE TO THE CALL FOR PROJECTS “ECONOMIC SECTORS”
5
2
3
CIENTIFIC PROJECTS FUNDED S BY CARNOT CONTRIBUTION
5
SCIENTIFIC & TECHNICAL RESOURCING
5
COLLABORATIVE PROJECTS
7
OMMUNICATION ACTIONS C AND DEVELOPMENT OF PARTNERING
8
PARTICIPATION IN INSTITUTIONAL AND SECTORAL EVENTS
8
INTERNATIONAL ACTIONS
8
4
KEY FIGURES DISTRIBUTION OF PARTNERSHIP REVENUES
9 9
RECORD YEAR FOR CONTRACTUAL A RESEARCH WITH THE SOCIO-ECONOMIC WORLD
10
RESEARCH PRODUCTS AND RESOURCES (2014)
11
ACTIVITY REPORT 2014
1
3
1
HIGHLIGHTS OF 2014
Obtaining the ISO 9001 : 2008 certification for the management and monitoring of partnering research activities Like any Carnot institute, CALYM is committed to respect the terms of the Charter of Carnot institutes which stipulates that “a Carnot institute sets up a quality approach for addressing any complaint from one of its contractors and agrees to respond promptly implementing the necessary means and best practices”. The process initiated in 2013 has achieved, in November 2014, the ISO 9001 : 2008 certification for the management and monitoring of the joint research activities of the institute. Awarded by the certification organization Euro-Quality System for a renewable period of three years, ISO 9001 : 2008 certification is the culmination of the quality approach implemented by the CALYM consortium as a result of its accreditation “Carnot institute” by the French Ministry of Research and Higher Education in 2011. The ISO 9001 : 2008 standard is based on a number of principles of quality management, including a strong customer focus, motivation and commitment from top management,
a process-driven approach and continuous search for improvement. Obtaining the ISO 9001 : 2008 certification was one of the objectives of the agreement between the French National Research Agency (ANR) and the CALYM Carnot institute. It was achieved through strong involvement of all administrations and personnel of the institute. For CALYM’s General Manager, Pascal Deschaseaux, «this certification reflects the strong commitment of the members of our institute to provide R&D responses adapted in form and substance to the needs expressed by socio-economic’s stakeholders in the field of lymphoma, currently the 6th worldwide and 1st blood cancer. It reinforces CALYM position as an international academic partner for industrial and public actors in this field, with a record number of collaborations”.
ACTIVITY REPORT 2014
CALYM Scientific and Partnering Day
The CALYM Carnot institute organized, on November 7, 2014, its 2nd Scientific and Partnering Day in Paris. In three quarters of the Carnot label,
4
CALYM wanted to report on its achievements and present the perspectives of the institute. The morning reserved for the teams of the consortium was dedicated to presentations of projects funded by the scientific resourcing and allowed numerous discussions among researchers. New perspectives for a possible Carnot 3 were also discussed. The afternoon was opened to our industrial and institutional partners and was an opportunity to demonstrate the strengths of CALYM to meet our partners’ R&D needs. The CELGENE and CLEVEXEL companies were invited to share their experience of working with the CALYM Carnot institute.
Response to the call for projects “Economic sectors” The call for projects “Valorisation Carnot institutes” launched by the French National Research Agency (ANR) - restricted to Carnot institutes - is dedicated to the specific action «Structuring of the offer in response to the needs of economic sectors»; it boasts a fund of € 120 million paid by the French State to the ANR in the context of the future investment program. CALYM, alongside 12 other Carnot institutes, participated in the Carnot application file “Health Medicine” sector (called FINDMED). These Carnot sectors are intended to aggregate around them
2
other ecosystem players, such technology research institutes, university hospital institutes, competitiveness clusters... Targets are French SMEs and medium-sized companies. The three funded axes are the following: Construction of a Carnot coordinated offer and structured by sector E stablishment of an organization of technology platforms networks Commitment of R&D projects with strong industrial innovation potential with SMEs / ETI The results of this call for projects were expected for the first quarter 2015.
SCIENTIFIC PROJECTS FUNDED BY CARNOT CONTRIBUTION
Carnot contribution received by the institute is used for scientific and technical resourcing. In accordance with actions engaged in previous years, LYSARC funded the research activities of its biostatisticians for its ancillary research and a project leader to collect and use clinical data of long-term follow-up studies. State contribution has also provided funding Clinical Research Associates (CRA) allocated to hospital centers with high recruitment potential of lymphoma
ACTIVITY REPORT 2014
Scientific & technical resourcing patients on non-funded strategic clinical trials. The LYSARC is equipped with a management tool for biological samples; this tool will also be shared with the whole institute for the management of the collection of viable cells (CeVi_collection). The results of these studies are used to generate new clinical hypotheses and new scientific programs and meet the objectives of CALYM R&D pillar “tools, platforms and processes related to clinical research”.
5
Seven research units benefit from Carnot contribution for their scientific resourcing:
ACTIVITY REPORT 2014
RESEARCH UNIT
6
TITLE OF THE PROJECT
INSERM U917 - MICA (Rennes)
Characterization of B lymphoma during their plasmablastic differentiation: interest in the model of B-cell lymphomas
CNRS - UMR 5239 (Lyon)
Study of cellular death in normal and tumoral B cells treated with antiCD20 monoclonal antibodies
INSERM UMR 1037 (Toulouse)
Post-transcriptional regulation in lymphoma : evaluation: evaluation of the expression and functions of several classes of non-coding RNAs
INSERM UMR 1037 CNRS ERL 5294 (Toulouse)
Fatal ADORAtion as new therapeutic targets in non-Hodgkin’s lymphomas
INSERM U1104 Centre d’Immunologie de Marseille-Luminy (Marseille)
Disruption oncogenic networks PTEN / AKT / MYC in acute lymphoblastic leukemia T cells
INSERM U 1111 (Lyon)
Impact of chronic bacterial infection on lymphomagenesis of NKT cells in mice and humans
INSERM U1009 (Gustave Roussy, Créteil)
Personalized medicine and lymphomas
Collaborative projects Call for collaborative projects The purpose of the call for projects was to encourage the emergence of scientific collaborative projects that meet the objectives of the 4 CALYM R&D pillars and may potentially lead to the development of collaborations with socio-economic partners.
Three projects were submitted and evaluated on their scientific quality and potential socio economic partnership. The three projects were funded for a period of 2 to 3 years.
RESEARCH UNIT
TITLE OF THE PROJECT
INSERM U917 - MICA (Rennes)
FLIRT - dynamics of tumor and microenvironment heterogeneity, phenotypic, genomic, genetic, and functional studies
INSERM 1068 CNRS UMR 7258 - CRCM (Marseille)
Blood-REPLAY
INSERM U955-9 (Créteil)
Targeting the T-cell receptor (TCR) signaling components and co-stimulatory molecules as novel therapeutic approaches to peripheral T-cell lymphoma (PTCL) patients
CeVi_Collection: Collection of viable cells
Many structuring actions helped to professionalize the biological sample collection network and to implement an effective quality system. First, the consortium agreement has been finalized and is being signed with all institutions involved in the project. Then, many procedures have been developed to fit into the overall quality system of the institute. Indeed, the activities of preparation, collection & hosting of cells will enrich the quality system already in place. A pre-audit will be conducted by the certification organism Euro-Quality System in June 2015, in order to better prepare the audit of ISO 9001 : 2008 certification, scheduled for the third quarter 2015.
This year, the network expanded with the inclusion of a new member: the UMR1037 of Toulouse Oncopole. The team specialized in molecular genetics of hematological malignancies offers a new source of samples. Two other centers are being included in the project: Montpellier university hospital and Gustave Roussy. In the centers, the collection is being actively pursued with the involvement of all actors: clinicians, biologists, technicians,... After less than two years of existence, the number of samples has increased dramatically with over 280 samples and more than 1,100 tubes collected.
ACTIVITY REPORT 2014
The project of collection of cell suspensions from tumor samples and non-lymphoid tumor, frozen in the form of viable cells, continues its evolution.
The collection has received three requests for samples for R&D programs with industrials and was able to meet two of them with a 100% satisfaction return.
7
3
COMMUNICATION ACTIONS AND DEVELOPMENT OF PARTNERING
Participation in institutional and sectoral events Les Rendez-Vous Carnot 2014 CALYM participated to “Les Rendez-Vous Carnot” on October, 8 and 9, 2014. This event was an opportunity to make contacts with new companies. In seven editions, “Les Rendez-Vous Carnot” has emerged as the major event of contractual R&D at the service of enterprise innovation. The event hosted in 2014 more than 2550 participants and 9000 business appointments.
During these appointments, CALYM initiated more than a dozen contacts with French very small companies, but also with public entities (universities, IRT).
International actions
ACTIVITY REPORT 2014
CALYM already generates the majority of its partnership research activity with international companies, including large pharmaceutical groups. International actions policy has been conducted to primarily target foreign RTO, SME and very small companies. CALYM is a member of GLOBAL CARE Initiative consortium (CGi) which promotes CALYM’s R&D offer internationally through coordinated actions (regional business trip and conference partnering) by two business developers targeting Europe, Asia and United States. Moreover, CALYM participated in international events with the presence of its General Manager and / or a CALYM member:
8
BIO international conventions (San Diego, USA), BIO Europe (Franckfurt, Allemagne), BIO Japan, BIO Europe Spring (Paris, France) CALYM has been approached by companies to be a partner in H2020 European projects with three letters of intent submitted and one project selected to submit a full proposal. All these actions have helped to present the Carnot label and scientific offer of CALYM to potential new international partners (academic, industrial). Many contacts have been made; scientific discussions are ongoing under confidentiality agreements. We hope an implementation of these actions by contracts signing in the short (2015) and especially the long term.
The focus this year was on the small / very small companies, with 65% of the industrial contacts in 2014 being on small / very small companies,
20% have targeted major pharmaceutical groups and 15% other types of businesses.
Europe
34
21 10
France
Chine
6 Etats-Unis
1 Inde
4
KEY FIGURES
Distribution of partnership revenues The revenue generated by the CALYM Carnot institute in 2014 is derived from four types of activities:
Non socio-economic contract research: contract research based on a direct research contract with a partner who does not fit in the Carnot contribution base The collaborative research that represents research projects funded by the government (state, local authorities, national agencies, European funds...)
Technical services
23 067
ACTIVITY REPORT 2014
Contract research that consists of research activities conducted in partnership with worldwide socio-economic stakeholders, in response to their needs
Contractual research within the socio-economic world
6 90 Contractual research without the socio-economic world
1 226 Collaborative research
5 8 Technical services
Proceeds in k€ (2014)
9
A record year for contractual research with the socio-economic world In 5 years, the contractual revenues have steadily increased, with a record year in 2014, as the contractual revenues reached € 23 million.
25 000 20 000 15 000 10 000 5 000
6 149
10 833
14 749
17 192
22 931
2010
2011
2012
2013
2014
0
Evolution of contractual research revenues within the socio-economic world (k€)
These revenues are generated principally by research contracts with foreign companies on international phase III trials.
5%
French Foreign
ACTIVITY REPORT 2014
55%
45%
Part of French vs. foreign companies
10
95%
Revenues amounts (M€)
Research products and resources (2014)
Work-force
Scientific resourcing
Intellectual property
Staff
216
PhD students
47
Post-Docs
26
Capacity to conduct research
37
CIFRE* contracts
2
Rank A publications
165
Total number of priority patents per year
12
Total number of priority patents in portfolio
24
Number of intellectual property shares generating income per year
0
Licence fees (in €) on intellectual property rights
0
ACTIVITY REPORT 2014
* CIFRE: Industrial agreements for training through research
11
CONTACTS Pascal Deschaseaux: General Manager
[email protected] Tél. +33 (0)4 72 66 93 33 Pr. Philippe Gaulard: Scientific Manager Véronique Staniek: Director of Operations
[email protected] Tél. +33 (0)4 72 24 41 71
